COOPER COMPANIES, INC.

Key metrics

Financial performance

Over the last 9 fiscal years COOPER COMPANIES, INC.'s revenue grew from $1.97B to $4.09B, a compound annual growth rate of 8.5%. Net profit margin compressed from 13.9% to 9.2% over the same period - every figure below comes from the company's audited annual filings.

Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.

Key statistics

Latest filings

Browse the full filing history (2,281 filings)

Recent press releases

• CooperCompanies Appoints Paul Keel to its Board of Directors2026-05-04

  “We are delighted to welcome Paul to our Board as a new Director,” said Colleen Jay, Chair of the Board of CooperCompanies. “His experience as a CEO in the medical device sector, along with a successful track record of leading complex global operations, will be a significant asset as Cooper continues to execute its strategy and create long-term value for patients, customers, and shareholders.”

• CooperCompanies Announces Release Date for Second Quarter 20262026-04-30

  The dial-in number for the call is 800-715-9871 and the conference ID is 6529381. A simultaneous audio webcast and subsequent replay can be accessed at www.investor.coopercos.com

• CooperCompanies Announces First Quarter 2026 Results2026-03-05

  First quarter 2026 revenue of $1.024 billion, up 6%, or up 3% organically, from last year's first quarter.

• CooperCompanies Announces Release Date for First Quarter 20262026-02-05

  The dial-in number for the call is 800-715-9871 and the conference ID is 6529381. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com .

Similar companies

The largest companies sharing COOPER COMPANIES, INC.'s SEC industry classification (ophthalmic goods).